• JUser: :_load: Unable to load user with ID: 44
Category: International

  •  Expands its portfolio to deliver high-quality drugs at an affordable cost

· India becomes the first market to witness Lilly’s entry in the branded generics segment

· Announces launch of drugs in Breast cancer and Colo-rectal cancer segment

Bangalore– December 10, 2013 : Eli Lilly and Company India, today announced entry in the branded generics segment with launch of Lil Therapeutics, an expansion of its oncology division that will help expand delivery of cancer drugs to patients at an affordable cost. India is the first country to witness the launch of branded generics from the house of Lilly. Today, Lilly launched four new drugs, Lilbecep (Epirubicin), Lilmantro (Anastrozole) and Lilxapla (Oxaliplatin) and Lilrincan (Irinotecan) for the treatment of patients with Breast cancer and Colo-rectal cancer respectively. These molecules are well established and time tested across the treatment algorithm of Oncology.


Lilly has been dedicated to delivering solutions that accelerate the pace and progress of cancer care and enhance the lives of people living with cancer. In India, Lilly has cultivated a strong equity in the Lung Cancer segment with innovative brands Gemcite and Alimta. With launch of Lil Therapeutics, Lillyaims to expand patients’ access to high-quality cancer drugs.

Commenting on the development, Mr. Edgard A Olaizola, Managing Director, Eli Lilly says “ Lilly is committed to improving outcomes for individual patients around the world. We understand that Cancer medicines of the highest quality continue to be an unmet need in India a nd as a responsible organization, we have been working over the years to make cancer drugs affordable to better serve Indian patients. This launch reaffirms our commitment to reach more patients and play a leading role in fighting cancer in this country”. He also mentioned, “ Though Lilly is launching branded generics in the oncology segment, we will continue to discover and develop innovative new therapies for patients worldwide.”

About Eli Lilly and Company


Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Indiana, Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com

Email address:

Prev Next
"ACCURA" MODEL ACT -III High Speed Double Rotary Tablet Presses
Pharmaceutical Labeling Equipment
The Power Times.in
The SME Times
 The Pharma Times News Portal
The Hotel Times
  • 1
  • 2
Prev Next
Omron Blood Pressure Monitor, HEM-7113
Automatic Capsule Filling Machine (PF-150)
Gelusil liquid antacid - Pfizer’s
The Varilux 3.0 range lenses - Essilor
Blossom Kochhar Aroma Magic Anti Pigmentation Serum
 The Property Times